Glaxo's Corixa deal a shot in the arm for vaccines (Reuters


Reuters - GlaxoSmithKline Plc's $300 million
planned acquisition of Corixa Corp. underlines the
British-based group's growing confidence in vaccines as a
future driver of growth, industry analysts said on Tuesday.

Read more...